03 Nov, 2025
The Regenerative Medicine Academy
The Regulatory Pathways & Ethical Practice in Regenerative Medicine Mini Course is designed for clinicians, researchers, and healthcare professionals who want to understand how to innovate safely and compliantly within the FDA’s regulatory framework.
This short foundational course provides the essential knowledge to help you stay within legal boundaries, protect patient safety, and communicate responsibly while advancing regenerative therapies.
You’ll learn how federal laws, ethical standards, and communication guidelines intersect, and how to apply them in real world clinical and business settings. Whether you’re offering PRP, adipose derived, or cell based therapies, this course gives you the clarity and confidence to grow the right way.
At the Regenerative Medicine Academy, we believe innovation must be paired with compliance and ethics. This mini course distills complex FDA and legal concepts into clear, actionable lessons that every regenerative professional can understand.
Each lesson combines expert insights, real world examples, and references to official FDA and FTC documents, helping you translate regulatory language into practical steps for your clinic, research project, or marketing strategy.
Learn how the FDA’s Expanded Access Program (EAP) provides a regulated pathway for compassionate use of investigational products.
Understand how the Right to Try Act empowers patients while emphasizing physician responsibility and product eligibility.
Explore how the Loper Bright v. Raimondo (2024) decision reshaped FDA authority, and what it means for regenerative medicine.
Master the ALCOA principles of ethical research, proper documentation, and transparent data handling in clinical practice.
Learn how to communicate ethically, stay compliant with FDA/FTC rules, and avoid common marketing pitfalls that lead to enforcement actions.
All courses offered by Regenerative Medicine Academy are for educational and training purposes only. They do not provide medical advice, establish standards of care, or authorize the clinical use of biologic materials, including PRP, adipose derived, or bone marrow derived products, for unapproved indications.
Participants are responsible for ensuring compliance with all applicable federal, state, and local regulations, including those of the FDA, FTC, and medical licensing boards, when applying techniques learned in these programs.
This course teaches legal and regulatory principles related to regenerative medicine in the United States. It covers foundational concepts of FDA jurisdiction and compliance considerations.
The course is designed for licensed healthcare professionals and other qualified providers interested in regulatory aspects of regenerative medicine. It may also benefit professionals involved in practice compliance and administration.
Yes, the training includes educational discussions about relevant FDA frameworks, oversight areas, and regulatory terminology. It focuses on legal foundations without offering legal advice.
This program is primarily structured as a classroom or webinar education format rather than hands-on clinical training. It emphasizes legal understanding and regulatory context.
Participants may receive a certificate of completion to document attendance and training participation. Certificates are for educational purposes only.
No, the course provides general educational content and is not a substitute for legal advice or professional regulatory consultation.
